Food allergy is a major health problem of growing concern, affecting more than 30 million people in US and Europe. Living with food allergy has a tremendous impact on the quality of life, with only trace amounts of allergens being able to trigger severe allergic reactions and potentially death. There are significant unmet medical needs for safe, efficacious, and convenient treatments of food allergies. FDA approved the first drug ever for food allergy immunotherapy (IT) in January 2020, thereby opening tremendous business potential within this emerging market. ALLEVIATE2 aims to develop novel drugs for food allergy sublingual IT (SLIT) with unmatched safety, efficacy and convenience profiles that would significantly improve quality of life of patients. This project will leverage the proprietary therapeutic strategy developed at DTU and successfully applied to develop drug candidates during the IFD funded ALLEVIATE project, as well as the combined research, clinical and business expertise of DTU, SickKids Hospital and ALK, the world leading allergy IT company. ALLEVIATE2 will transfer the therapeutic strategy from peanut allergy IT drug candidates to multiple-nut and complete the preclinical drug discovery phase for peanut and multiple-nut SLIT. Market analysts forecast that ALK can capture a 2-3 BUSD market share in the emerging food allergy IT market, and ALLEVIATE2 represents the first pipeline drugs in the endeavour to realise the growth potential.